Acquisitions, Collaboration, License and Other Strategic Agreements (Details) - USD ($)			1 Months Ended			3 Months Ended		12 Months Ended
	Jan. 16, 2019	Apr. 03, 2017	Jun. 30, 2018	Feb. 28, 2017	Jan. 31, 2017	Mar. 31, 2019	Sep. 30, 2017	Dec. 31, 2018	Dec. 31, 2017
Prasco, LLC
Collaborative Agreements
Renewal term						1 year
Endoceutics, Inc.
Collaborative Agreements
Consideration recorded									$ 83,500,000
Payments related to collaborative arrangement		$ 50,000,000
Number of shares issued under arrangement (in shares)		600,000
Net shares issued in connection with license agreement, value		$ 13,500,000
IPR&D expense									5,800,000
Palatin Technologies, Inc.
Collaborative Agreements
Payments related to collaborative arrangement				$ 60,000,000
Out-of-pocket expenses (up to)				25,000,000
Intrarosa | Endoceutics, Inc.
Collaborative Agreements
Payments related to collaborative arrangement							$ 6,000,000
Out-of-pocket expenses (up to)							$ 20,000,000
Intrarosa | Endoceutics, Inc. | Developed technology rights
Collaborative Agreements
Finite-lived intangible assets									77,700,000
Intrarosa | Endoceutics, Inc. | Delivery Of Intrarosa Launch Quantities
Collaborative Agreements
Payments related to collaborative arrangement									$ 10,000,000
Intrarosa | Endoceutics, Inc. | First Anniversary Of Closing
Collaborative Agreements
Payments related to collaborative arrangement								$ 10,000,000
Intrarosa | Endoceutics, Inc. | Tiered Royalties
Collaborative Agreements
Potential milestone payment, triggering event, sales				$ 150,000,000
Royalty percentage, maximum		25.00%		25.00%
Net sales threshold, future contingent payments				$ 1,000,000,000
Period after first commercial sale				10 years
Vyleesi Products | Palatin Technologies, Inc. | Regulatory Milestone Achievement, Acceptance By U.S.Food And Drug Administration Of New Drug Application
Collaborative Agreements
Payments related to collaborative arrangement			$ 20,000,000
Vyleesi Products | Palatin Technologies, Inc. | Tiered Royalties
Collaborative Agreements
Period after first commercial sale					10 years
Perosphere Pharmaceuticals Inc.
Collaborative Agreements
Consideration recorded	$ 50,000,000
Payments of asset acquisitions	40,000,000
Cancellation of convertible note	10,000,000
Other liabilities	6,200,000
Cash consideration	$ 60,800,000
Discount rate	34.00%
Perosphere Convertible Note | Convertible Debt | Perosphere Pharmaceuticals Inc.
Collaborative Agreements
Aggregate principal amount of debt issued	$ 10,000,000.0
Perosphere Term Loan | Line of Credit | Perosphere Pharmaceuticals Inc.
Collaborative Agreements
Payment for debt extinguishment	$ 12,000,000
Failure To Supply A Certain Percentage Of Product | Prasco, LLC
Collaborative Agreements
Failure to supply, penalties						$ 3,600,000